The Human Immunology Research Teams are expected to:

• Generate new scientific knowledge that will advance our understanding of human immunology as it relates to autoimmune diseases, with appropriate consideration of sex-related mechanisms, in order to improve the health of Canadians living with autoimmune diseases.
• Leverage the Standardization Core by encouraging collaboration with the Core and utilization of the Core’s research methodologies where possible.
• Develop and strengthen research capacity by providing training opportunities to the next generation of human immunology researchers in the field of autoimmune diseases.

The specific objectives of this funding opportunity are:

• to support planning activities, partnership development and/or increasing understanding of the health research landscape that will contribute to the advancement of research consistent with the mandate of CIHR; and/or;
• to support dissemination events/activities that focus on the communication of health research evidence to the appropriate researcher and/or knowledge user audience(s), tailoring the message and medium as appropriate.

The Geroscience Demonstration Grants are expected to:

• Accelerate, catalyze, and build capacity for research on the early prevention of chronic diseases in aging using a geroscience approach
• Support the creation of new knowledge to improve our understanding of the relationship between mechanisms in the biological processes of aging and the development of one or several chronic conditions (e.g., diabetes, cancer, neurodegenerative diseases, arthritis, cardio-respiratory diseases)
• Support research using a geroscience approach that could lead to potential clinical impacts.

The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical PH- and TBI-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).  The CDMRP provides PH/TBIRP execution management support for DHP core research program areas, including the Joint Program Committee 6/ Combat Casualty Care Research Program (JPC-6/CCCRP).  JPC-6/CCCRP provides strategic oversight for the PH/TBI funds associated with this funding Program Announcement.  The Defense Health Agency is working in collaboration with the U.S. Department of Veterans Affairs (VA) and other Federal agencies on research efforts to improve the lives of Service members and Veterans affected by traumatic brain injury, posttraumatic stress disorder, and other mental health conditions.

The FY18 PH/TBIRP Program Announcement and General Application Instructions for the following award mechanism is posted on the Grants.gov website.

http://cdmrp.army.mil/funding/phtbi

FY18 PHTBIRP Joint DoD and VA Long-term Impact of Military-relevant Brain Injury Consortium (LIMBIC) – Preproposal due October 8

• Independent investigators at all academic levels (or equivalent)
• Supports a consortium conducting a single large longitudinal study and supporting sub-studies to analyze a large TBI cohort to include Service member and Veterans.
• Applicants must be able to demonstrate the ability to enroll relevant cohorts, including military and Veteran populations, and follow them over time.
• Applicants must address the Required Research Elements outlined in the Program Announcement.
• Applications should describe a single large longitudinal cohort study and a minimum of four related sub-studies.
• All projects shall be limited to clinical and epidemiological research.
• Clinical trials are not supported.
• Coordinating Center and study sites must apply through a single application.
• Preproposal is required; application submission is by invitation only.
• Maximum allowable costs (direct and indirect) are $25M via the DoD.
• Up to an additional $5M per year for 5 years will be provided by the VA to VA sites, depending on availability of funds.
• Maximum period of performance is 5 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical traumatic brain injury (TBI)- and psychological health (PH)-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation appropriation.  The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP).  The managing agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMRP.

The FY18/19 PH/TBIRP will solicit research applications for the following CTRR Focus Areas:

Mechanisms of Recovery following isolated or cumulative TBI(s) in Service member-relevant injuries:  Clinical research in human subjects that measures physiologic responses to cognitive rehabilitation with the intent to better understand how rehabilitation remediates cognitive or sensorimotor deficits, and ultimately to optimize rehabilitation prescription.

Ecological Assessment:  Investigation of outcome measures focused on military-specific tasks that inform return-to-duty/participation decisions following rehabilitation in patients with TBI. 

Cognitive Rehabilitation:  Evaluation of rehabilitation intervention effectiveness in remediating cognitive impairments and functional limitations after TBI. 

https://www.grants.gov/web/grants/search-grants.html

CTRR – Clinical Research Award (CTRR-CRA) – Preproposal due September 24, 2018

Independent investigators at all academic levels (or equivalent)

·        Supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI.

·        Supported research can include preclinical studies using human subjects or samples and observational or mechanistic clinical research studies.

·        Clinical trials are not allowed.

·        Preclinical research using animals is not allowed.

·        Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

Preproposal is required; application submission is by invitation only.

·       Maximum funding of $2.0M for total costs (includes direct and indirect costs).

·       Maximum period of performance is 3 years.

CTRR – Clinical Trial Award (CTRR-CTA) – Preproposal due September 24, 2018

Independent investigators at all academic levels (or equivalent)

·        Supports small, single-site, Phase I clinical trials to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI in Service members, Veterans, and other individuals.

·        Interventions should be limited, existing, and manualized.  Studies may include seeking to optimize dosing in existing interventions.

·        Preclinical studies are not allowed.

·        Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

Preproposal is required; application submission is by invitation only.

·       Maximum funding of $2.0M for total costs (includes direct and indirect costs).

·       Maximum period of performance is 3 years.

CTRR – Clinical Trial Development Award (CTRR-CTDA) – Preproposal due September 24, 2018

Independent investigators at all academic levels (or equivalent)

·       Supports design and development of the necessary research resources that will serve as a foundation for investigator-initiated clinical trials as described above under CTRR – Clinical Trial Award (CTRR-CTA)

·       Final supporting studies required for approval of Investigational New Drug Applications/Investigational Device Exemptions (IND/IDE-enabling) are allowed.  Other preclinical studies are not allowed. 

·       Clinical trials are not allowed within the period of performance of the CTRR-CTDA.

·       Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

Preproposal is required; application submission is by invitation only.

·      Maximum funding of $200,000 for total costs (includes direct and indirect costs).

·       Maximum period of performance is 12 months.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBRap.org

The Dr. R. K. Dewar Medical Research Grant was established in 1987 by Ms. Helen Dewar to honour the life and work of her brother Dr. Robert Kerr Dewar. Dr. Dewar had faith in the future and progress of medical science and had a keen interest in cutting edge research of his day. He was particularly interested in Neuro-Regeneration and Molecular Biology. When selecting R. K. Dewar Grants our Selection Committee looks for the following elements in successful proposals:

• Addresses a small research project or marketing for a health care charity
• Makes an impact on Health Care in Thunder Bay
• Seeks to assist in the future progress of medicine.
• Are organized and well written.

The Fields Institute is currently accepting proposals for the October 15, 2018 competition cycle.

Deadlines

Deadlines for general scientific activity proposal applications are February 15, June 15, and October 15 of each year. A lead time of at least nine (9) months is requested between the proposal application deadline and the date of the event. Applications are reviewed after each deadline.

Proposals requesting funding of up to $25,000 are considered by the Institute's Directorate and decisions are normally announced within six (6) weeks of each deadline. Proposals requesting over $25,000 will be considered by the Institute's Scientific Advisory Panel (SAP) and should be submitted by the February 15 and October 15 deadlines only, with decisions normally announced by early June or December of each year.

Proposals for General Scientific Activities

General scientific activities (GSA) generally consist of a period of one day to one month of concentrated activity in topics of current research interest in the mathematical sciences and should include opportunities for the involvement of young scientists and graduate students. A large number of general scientific activities are scheduled for each academic year. Topics supported through general scientific activities are often newly emerging areas in the mathematical sciences in Canada and add breadth to the range of research supported by the Fields Institute. The activities may be in the form of workshops, seminars, conferences and/or summer schools.

The GSA program is the principal method by which Fields engages a wider community to input into its scientific programs and an important way for Fields to stay connected to Principal Sponsoring and Affiliate Universities. Our proposal mechanism was devised to invite these activities. The Directorate, consulting with referees and members of the SAP, makes decisions about support following a rigorous selection process. Applicants may apply for financial and/or logistical support from Fields. Logistical support options are described here

The broad purpose of this fund is to encourage Canadian academics to undertake projects of relevance to accounting academic or professional communities. The research under this program need not lead to publication in a scholarly journal, although it may lead to one or more such publications. The research project may result in a report that is both useful to practitioners and provides background in an area that could be the subject of further academic exploration.

This funding opportunity is expected to:

• Generate preliminary observations, data or knowledge into the potential benefits and harms of cannabis and/or cannabis use
• Support projects which have the potential to generate high impact results and/or innovative research proposals, research tools, techniques, devices, inventions or methodologies
• Facilitate consideration and application of new evidence to inform ongoing and future development of policies, practices and programs related to cannabis